Evonik Industries and Eli Lilly and Company (Lilly) have announced the renewal of a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly human and veterinary drug products.
Dr Jean-Luc Herbeaux, head of Evonik’s Health Care Business Line, explained: “The renewal of this supply agreement is clear evidence of the continued excellent collaboration between Evonik and Lilly. Evonik thanks Lilly for their great vision in transferring a well-maintained asset to Evonik in 2010 – and for their confidence in Evonik and our Tippecanoe facility as a reliable and dependable CDMO, both now, and in the future.”
Evonik acquired the Tippecanoe site in Lafayette in the US State of Indiana from Lilly, a global healthcare leader, in January 2010. The facility has been operating as a contract development and manufacturing organization (CDMO) for the pharmaceutical industry since then. It now proudly serves more than 20 Evonik customers including Lilly. In addition to becoming a core element of Evonik’s international contract manufacturing business, the facility is one of the world’s largest CDMO with 170 cubic meters of High Potency APIs (HPAPIs) capacity and a total of 860m3 of cGMP manufacturing.
The Lafayette site employs approximately 600 people, and leverages both the onsite and global expertise of Evonik’s Health Care Business to support its pharmaceutical customers for the reliable scale-up in production of complex molecules to meet clinical and commercial demand.
Evonik’s Health Care Business Line serves as a best-in-class strategic partner to the pharmaceutical, medical device and food ingredients industry. The broad product portfolio, deep technical know-how and advanced global capabilities create value by helping our customers reduce risk, enhance quality, improve efficiencies and differentiate their brands. The product and service portfolio includes API contract manufacturing, pharmaceutical excipients, advanced food ingredients, amino acids, cell culture ingredients as well as oral and parenteral drug delivery technologies.